Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has announced a registered direct offering aimed at raising approximately $480,000. This financial move involves the sale of 3,380,276 shares of common stock at $0.142 per share, with the offering priced at the market and expected to close around January 6, 2025. The proceeds are earmarked for several critical areas, including market development, clinical evidence gathering, product development, quality improvements, and general corporate purposes.
The centerpiece of Aclarion's innovation is the Nociscan platform, a Software as a Service (SaaS) solution that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, and augmented intelligence algorithms. This technology is designed to assist physicians in identifying painful discs in the lumbar spine, offering a novel approach to diagnosing and treating chronic low back pain, a condition that plagues millions globally.
Nociscan's methodology involves analyzing MRS data from lumbar disc MRI scans through cloud-based algorithms that process chemical biomarkers linked to disc pain. This process provides physicians with valuable insights into the potential sources of a patient's pain, thereby facilitating more informed treatment decisions and potentially better patient outcomes.
Dawson James Securities, Inc. serves as the sole placement agent for this offering, which is conducted under a shelf registration statement on Form S-3, declared effective by the Securities and Exchange Commission (SEC) on September 23, 2024. This offering could significantly impact Aclarion's ability to advance its technology, expand its clinical evidence base, and solidify its presence in the chronic low back pain diagnosis market.
The chronic low back pain market presents a vast opportunity due to the high prevalence of the condition and the existing challenges in its diagnosis. Aclarion's Nociscan platform seeks to overcome these hurdles by delivering objective, data-driven insights that complement traditional diagnostic methods.
Potential investors should consider the inherent risks of investing in the medical technology sector, including those related to product development, regulatory approvals, and market acceptance. Aclarion has cautioned that forward-looking statements in their announcement are subject to various uncertainties that could affect actual outcomes.
For further details on the offering, interested parties can access the prospectus supplement and accompanying prospectus on the SEC's website at https://www.sec.gov. The offering's completion hinges on meeting standard closing conditions.
This funding initiative highlights the growing interest in medical technologies capable of enhancing patient care and tackling major healthcare issues. As Aclarion progresses with its plans to allocate these funds, the advancements in its Nociscan technology and its implications for chronic low back pain management will be closely monitored by both the medical community and investors.
